The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups. However, for patients with HR-negative and HER2-null tumors, SG showed better results when used as the first treatment. For other patient groups, there was no clear advantage to starting with one drug over the other.
The study found that the cancer drug T-DXd worked better for patients whose tumors are hormone receptor (HR)-positive, helping them stay on treatment longer than those taking SG, across all HER2-negative groups. However, for patients with HR-negative and HER2-null tumors, SG showed better results when used as the first treatment. For other patient groups, there was no clear advantage to starting with one drug over the other.
という事で、要は患者ごとに効きやすい薬をoptimizeするprecision medicineってわけね。
なかなかhotな事してるね。
ただ繰り返しになるけど競合も多そう。
投資の参考になりましたか？